drugset / Trial / NCT04944966
Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria
Phase 2
Completed
12 enrolled
Ifakara Health Institute
Muhimbili University of Health and Allied Sciences · collabNational Institute for Medical Research, Tanzania · collabSwiss Tropical & Public Health Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Antimalarial Herbal medicine known as Maytenus senegalensis will be evaluated for its safety, tolerability and efficacy among Tanzanian male adults aged 18 to 45 years. The first primary objective is to assess the safety and tolerability of malaria herbal remedy of Maytenus senegalensis among healthy male adults aged 18 to 45 years in Tanzania. And the second objective is to evaluate the safety, tolerability as well as efficacy of malaria herbal remedy Maytenus senegalensis (MALHERBAL) for the treatment of Tanzanian adults aged 18 to 45 years with uncomplicated malaria compared to Artemether-lumefantrine.
Timeline
- Start
- 2021-06-02
- Primary completion
- 2022-09-25
- Completion
- 2022-09-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artemether-lumefantrine | Unknown | 400 mg | Oral |
| Subject | Artemether-lumefantrine | Unknown | 600 mg | Oral |
| Subject | Artemether-lumefantrine | Unknown | 800 mg | Oral |